Publication Date:
2008-08-16
Description:
Previous attempts have shown the potential of T cells in immunotherapy of cancer. Here, we report on the clinical activity of a bispecific antibody construct called blinatumomab, which has the potential to engage all cytotoxic T cells in patients for lysis of cancer cells. Doses as low as 0.005 milligrams per square meter per day in non-Hodgkin's lymphoma patients led to an elimination of target cells in blood. Partial and complete tumor regressions were first observed at a dose level of 0.015 milligrams, and all seven patients treated at a dose level of 0.06 milligrams experienced a tumor regression. Blinatumomab also led to clearance of tumor cells from bone marrow and liver. T cell-engaging antibodies appear to have therapeutic potential for the treatment of malignant diseases.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Bargou, Ralf -- Leo, Eugen -- Zugmaier, Gerhard -- Klinger, Matthias -- Goebeler, Mariele -- Knop, Stefan -- Noppeney, Richard -- Viardot, Andreas -- Hess, Georg -- Schuler, Martin -- Einsele, Hermann -- Brandl, Christian -- Wolf, Andreas -- Kirchinger, Petra -- Klappers, Petra -- Schmidt, Margit -- Riethmuller, Gert -- Reinhardt, Carsten -- Baeuerle, Patrick A -- Kufer, Peter -- New York, N.Y. -- Science. 2008 Aug 15;321(5891):974-7. doi: 10.1126/science.1158545.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Interdisciplinary Phase I/II Unit of the University of Wurzburg, Klinikstrasse 6-8, 97070 Wurzburg, Germany.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/18703743" target="_blank"〉PubMed〈/a〉
Keywords:
Antibodies, Bispecific/*administration & dosage/adverse
;
effects/immunology/therapeutic use
;
Antineoplastic Agents/*administration & dosage/adverse effects/therapeutic use
;
B-Lymphocytes/immunology
;
Humans
;
Immunologic Memory
;
Immunophenotyping
;
Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy/immunology
;
Lymphocyte Count
;
Lymphoma, B-Cell/*drug therapy/immunology
;
Lymphoma, Follicular/*drug therapy/immunology
;
Lymphoma, Mantle-Cell/*drug therapy/immunology
;
Recurrence
;
T-Lymphocytes/immunology
;
T-Lymphocytes, Cytotoxic/*immunology
Print ISSN:
0036-8075
Electronic ISSN:
1095-9203
Topics:
Biology
,
Chemistry and Pharmacology
,
Computer Science
,
Medicine
,
Natural Sciences in General
,
Physics
Permalink